1. Home
  2. |Professionals
  3. |Kurt Machemer

Kurt Machemer

Partner | He/Him/His
Partner | He/Him/His
a21hY2hlbWVyQGNyb3dlbGwuY29t
VCardLinkedIn
VCardLinkedIn

Areas of Focus

Overview

Kurt Machemer focuses his practice on meeting the business and legal needs of emerging growth companies in the life sciences and technology sectors, as well as venture capitalists and other investors in early-stage companies. He represents organizations at various stages of development, including companies with marketed pharmaceutical products, medical devices/diagnostics, and various innovative drug development programs.

Kurt helps clients through a variety of complex transactions, including offerings of equity and debt securities, acquisitions and dispositions of private companies, joint ventures, R&D collaborations, and other strategic partnerships. In addition, he regularly counsels entrepreneurs, senior management and boards of directors on pre-formation, formation, governance, and transactional matters. Kurt also advises companies and senior executives on employment matters and leading academicians in their interactions with industry.

Kurt is an active participant in the Big Brothers of Massachusetts Bay mentorship program, a youth sports coach, a member of the Nominating Committee to the Board of Directors at the Winchester Swim & Tennis Club, and a member of the Board of Directors of Pathway to Possible, a 501(c)(3) non-profit organization dedicated to providing housing, support, and advocacy for individuals with cognitive and developmental disabilities. Kurt has previously served as a domestic violence prevention advocate.

Career & Education

    • Attorney, AmLaw 200 firm
    • Attorney, Boston-based firm
    • Attorney, AmLaw 200 firm
    • Attorney, Boston-based firm

    • University of Michigan, B.A.
    • Boston University School of Law, J.D.
    • University of Michigan, B.A.
    • Boston University School of Law, J.D.

    • Massachusetts
    • Massachusetts

Representative Matters

Before joining Crowell Life Sciences in 2025, Kurt was Principal at Faber Daeufer & Itrato PC. In this capacity, he led numerous formations, equity financings, acquisitions, mergers and reverse mergers, and collaborations for a wide cross-section of clients in the life sciences ecosystem. Select representative matters during his time at Faber include:

  • Formation and equity financing of an innovative antibody discovery biopharmaceutical company by multiple investment firms and venture capital partners
  • Financings of Actithera by M Ventures and Arkin Bio-Holdings
  • Acquisition of Proteros biostructures GmbH’s ownership stake in Rodin Therapeutics by Alkermes
  • Equity financing of NextPoint Therapeutics by Leaps by Bayer, Sanofi Ventures, MPM Capital Management, Dana-Farber Cancer Institute, Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners
  • Foundation for Angelman Syndrome Therapeutics (FAST) in its venture with Couragene, Inc. to create CourageAS, Inc.
  • Equity financing of Rila Therapeutics
  • Praeventix in connection with a private investment by Tellus BioVentures
  • In-license of foundational intellectual property from academia and equity financing of NextPoint Therapeutics by MPM, Binney Street Capital, and Simcere Pharmaceutical
  • Foundation for Angelman Syndrome Therapeutics’ (FAST) collaboration with the University of Pennsylvania
  • Equity financing of Claris Biotherapeutics by Novo Ventures and others
  • Equity investment by Novo A/S in ZS Pharma